Avoiding Cisplatin-Related Hearing Loss, Including Implementing Sodium Thiosulfate as Otoprotectant Into Daily Pediatric Clinical Practice: Proceedings Based on Evidence and Expert Opinion From the Ototoxicity Taskforce of the SIOP Supportive Care Ne

Objectives: Sodium thiosulfate (STS) has recently been approved as an otoprotectant for systemic use in pediatric cancer patients receiving cisplatin treatment for localized, nonmetastatic solid tumors by the Food and Drug Administration, European Medicines Agency, and Medicines and Healthcare Products Regulatory Agency. While incorporating STS into the current standard of care pediatric practice, questions about uniform, timely, and safe administration are raised that may benefit from additional guidance. Design: Recognizing that advancing clinical practice presents multiple challenges, an international onco-ototoxicity prevention task force, including experts in pediatric oncology, audiology, and pharmacology, was established to identify potential barriers to the implementation of otoprotection and to offer practical solutions for clinical services for children exposed to cisplatin, based on available evidence, as well as consensus where data are less robust. This task force held several online meetings and a working group session at the annual SIOPE meeting in Milan in May 2024, where the challenges for implementing STS were outlined and addressed. Results: Nine key challenges were identified, including, for example, the timing of both cisplatin infusion and STS administration, the optimal integration of STS into existing treatment protocols, potential drug interactions, and relevant economic considerations. Conclusion: In this article, we propose practical steps to address these challenges, informed by the existing literature and expert opinion, incorporating recommendation statements from the international onco-ototoxicity prevention task force on behalf of the SIOP Supportive Care Network, to facilitate the implementation of STS in children with localized, nonmetastatic disease.

Authors

Institutions

Publication Details

Journal
Ear and Hearing
Published
2026-06-26
DOI
https://doi.org/10.1097/aud.0000000000001856
Primary Topic
Hearing, Cochlea, Tinnitus, Genetics
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Avoiding Cisplatin-Related Hearing Loss, Including Implementing Sodium Thiosulfate as Otoprotectant Into Daily Pediatric Clinical Practice: Proceedings Based on Evidence and Expert Opinion From the Ototoxicity Taskforce of the SIOP Supportive Care Ne

Alex E. Hoetink, Pia Delano, Stefan Rutkowski, Vassilios Papadakis et al.
Ear and Hearing
Hearing, Cochlea, Tinnitus, Genetics
article

Avoiding Cisplatin-Related Hearing Loss, Including Implementing Sodium Thiosulfate as Otoprotectant Into Daily Pediatric Clinical Practice: Proceedings Based on Evidence and Expert Opinion From the Ototoxicity Taskforce of the SIOP Supportive Care Ne

Alex E. Hoetink, Pia Delano, Stefan Rutkowski, Vassilios Papadakis, Alwin D. R. Huitema, Gabriele Calaminus, Marry M. van den Heuvel‐Eibrink, Claudia Pasqualini, Martine van Grotel, Michael Sullivan, Kaukab Rajput, Furqan Shaikh, Antoinette am Zehnhoff‐Dinnesen, Gareth J. Veal, Nienke Streefkerk, M Caniza, Amirhossein Masroor, M Van der Wetering, A Lindsay Frazier, Kristin Knight, Allison F. O'neill, Penelope R. Brock, Brice Fresneau, Heather Weerdenburg, James I. Geller, Marc Ansari, Nathalie Gaspar, Eric Bouffet
article en

Abstract

Objectives: Sodium thiosulfate (STS) has recently been approved as an otoprotectant for systemic use in pediatric cancer patients receiving cisplatin treatment for localized, nonmetastatic solid tumors by the Food and Drug Administration, European Medicines Agency, and Medicines and Healthcare Products Regulatory Agency. While incorporating STS into the current standard of care pediatric practice, questions about uniform, timely, and safe administration are raised that may benefit from additional guidance. Design: Recognizing that advancing clinical practice presents multiple challenges, an international onco-ototoxicity prevention task force, including experts in pediatric oncology, audiology, and pharmacology, was established to identify potential barriers to the implementation of otoprotection and to offer practical solutions for clinical services for children exposed to cisplatin, based on available evidence, as well as consensus where data are less robust. This task force held several online meetings and a working group session at the annual SIOPE meeting in Milan in May 2024, where the challenges for implementing STS were outlined and addressed. Results: Nine key challenges were identified, including, for example, the timing of both cisplatin infusion and STS administration, the optimal integration of STS into existing treatment protocols, potential drug interactions, and relevant economic considerations. Conclusion: In this article, we propose practical steps to address these challenges, informed by the existing literature and expert opinion, incorporating recommendation statements from the international onco-ototoxicity prevention task force on behalf of the SIOP Supportive Care Network, to facilitate the implementation of STS in children with localized, nonmetastatic disease.

Ear and Hearing
University of Geneva (CH), Cincinnati Children's Hospital Medical Center (US), Royal Children's Hospital (AU), Harvard University (US), Inserm (FR), Universität Hamburg (DE), Oregon Health & Science University (US), University of Toronto (CA), Utrecht University (NL), University Hospital Bonn (DE), Great Ormond Street Hospital for Children NHS Foundation Trust (GB), Hospital for Sick Children (CA), Institut Gustave Roussy (FR), The Netherlands Cancer Institute (NL), University Medical Center Utrecht (NL), University Hospital Münster (DE), Centre de recherche en Epidémiologie et Santé des Populations (FR), University Hospital of Geneva (CH), University Medical Center Hamburg-Eppendorf (DE), Oncode Institute (NL), Aga Khan Development Network (CH), Children's Hospital Agia Sophia (GR), Princess Máxima Center (NL), SickKids Foundation (CA), Iaso Children’s Hospital (GR), Wilhelmina Children's Hospital (NL), Dana-Farber/Boston Children's Cancer and Blood Disorders Center (US), Newcastle University (GB)
Openalex Percentile: Top 8%
Hearing, Cochlea, Tinnitus, Genetics
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.